


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPLICATION FOR CLINICAL TRIAL OF TQC3302 “ICS/LAMA/LABA SOFT MIST
INHALATION FORMULATION” APPROVED BY NMPA

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Group’s independently developed Category 2.3 modified new drug, TQC3302 “ICS/LAMA/LABA Soft Mist Inhalation Formulation”, has received clinical trial approval from the National Medical Products Administration of China (NMPA), and is intended for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

TQC3302 is a triple-combination formulation comprising ICS (inhaled corticosteroid), LAMA (long-acting muscarinic antagonist), and LABA (long-acting β 2-adrenergic agonist), developed based on the Group’s soft mist inhalation technology platform. Preclinical studies have confirmed the safety of the triple-combination formulation.

Soft mist inhalers represent a new generation of inhalers that deliver medication to patients in the form of a slow-moving fine mist through mechanical actuation. Compared with conventional nebulizers or dry powder inhalers, soft mist inhalers provide a longer aerosol release time and slower velocity, reducing drug loss in the oropharyngeal region and achieving a higher rate of pulmonary deposition, while requiring less hand-mouth coordination from patients, making them suitable for populations with administration difficulties, such as children and the elderly.

At present, no ICS/LAMA/LABA triple-combination soft mist inhalation formulation has been approved for marketing globally. The Group is actively advancing the clinical development of TQC3302, which is expected to offer additional treatment options for COPD patients.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 5 August 2025

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.

* *For identification purpose only*